PHILADELPHIA, Dec. 7, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (NASDAQ: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, today announced that Patrick T. Mooney, M.D., Chairman & CEO of Echo Therapeutics, will present at the Oppenheimer 22nd Annual Healthcare Conference.
Dr. Mooney will make a presentation to prospective corporate partners and investors on Wednesday, December 14th at 3:20 PM ET. The Company’s presentation will be delivered at the Waldorf Astoria Hotel in New York City.
About Echo Therapeutics
Echo is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units. Echo is also developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation for delivery of topical pharmaceuticals.
For More Information:
Christine Olimpio
Director, Investor Relations & Corporate Communications
(215) 717-4104
SOURCE Echo Therapeutics, Inc.
